Suppr超能文献

循环血栓素-2 水平与 2 型糖尿病心力衰竭住院、左心室重构和舒张功能的前瞻性关联。

Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes.

机构信息

Department of Medicine, School of Clinical Medicine, University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong.

State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Pok Fu Lam, Hong Kong.

出版信息

Cardiovasc Diabetol. 2022 Nov 5;21(1):231. doi: 10.1186/s12933-022-01646-x.

Abstract

BACKGROUND

Circulating thrombospondin-2 (TSP2) levels were associated with the development of heart failure (HF) in recent studies. However, these studies included only a minority of patients with type 2 diabetes, which is associated with an increased HF risk. As hyperglycemia induces TSP2 expression and its tissue expression increases in type 2 diabetes, we investigated the prospective association of circulating TSP2 with incident HF hospitalization (HHF), and its associations with longitudinal changes of echocardiographic parameters in type 2 diabetes.

METHODS

Baseline serum TSP2 levels were measured in 4949 patients with type 2 diabetes to determine its association with incident HHF using multivariable Cox regression analysis. In the echocardiographic study, baseline serum TSP2 levels were measured in another 146 patients with type 2 diabetes but without cardiovascular diseases who underwent detailed transthoracic echocardiography at baseline and after 1 year.

RESULTS

Over a median follow-up of 7.8 years, 330 of 4949 patients (6.7%) developed incident HHF. Baseline serum TSP2 levels were independently associated with the development of HHF (HR 1.31, 95%CI 1.06-1.62, p = 0.014) after adjustments for baseline conventional cardiovascular risk factors, atrial fibrillation, estimated glomerular filtration rate, albuminuria and high-sensitivity C-reactive protein level, use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop-diuretics, aspirin, insulin, metformin and sodium-glucose co-transporter 2 inhibitors. Moreover, baseline serum TSP2 levels were independently associated with increase in average E/e' and left atrial volume index (p = 0.04 and < 0.01, respectively).

CONCLUSION

Serum TSP2 levels were independently associated with both incident HHF and deterioration in diastolic function in type 2 diabetes.

TRIAL REGISTRATION

Not Applicable.

摘要

背景

最近的研究表明,循环血栓反应蛋白-2(TSP2)水平与心力衰竭(HF)的发展有关。然而,这些研究仅包括少数 2 型糖尿病患者,而 2 型糖尿病患者 HF 风险增加。由于高血糖诱导 TSP2 表达,且其组织表达在 2 型糖尿病中增加,我们研究了循环 TSP2 与 2 型糖尿病患者事件性 HF 住院(HHF)的前瞻性关联,及其与 2 型糖尿病患者超声心动图参数的纵向变化的关联。

方法

对 4949 例 2 型糖尿病患者进行基线血清 TSP2 水平测量,以确定多变量 Cox 回归分析与事件性 HHF 的关系。在超声心动图研究中,对另外 146 例无心血管疾病的 2 型糖尿病患者进行基线血清 TSP2 水平测量,这些患者在基线和 1 年后接受了详细的经胸超声心动图检查。

结果

在中位随访 7.8 年期间,4949 例患者中有 330 例(6.7%)发生事件性 HHF。校正基线常规心血管危险因素、房颤、估计肾小球滤过率、白蛋白尿和高敏 C 反应蛋白水平、血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、袢利尿剂、阿司匹林、胰岛素、二甲双胍和钠-葡萄糖共转运蛋白 2 抑制剂后,基线血清 TSP2 水平与 HHF 的发生独立相关(HR 1.31,95%CI 1.06-1.62,p=0.014)。此外,基线血清 TSP2 水平与平均 E/e'和左心房容积指数的增加独立相关(p=0.04 和 <0.01)。

结论

血清 TSP2 水平与 2 型糖尿病患者的事件性 HHF 和舒张功能恶化均独立相关。

试验注册

不适用。

相似文献

3
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.达格列净对 2 型糖尿病心力衰竭和死亡的影响。
Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.
4
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.恩格列净在常规临床治疗中心衰住院风险的研究
Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

引用本文的文献

1
Clinical Insights from Proteomics in Heart Failure.心力衰竭蛋白质组学的临床见解
Curr Heart Fail Rep. 2025 Mar 10;22(1):12. doi: 10.1007/s11897-025-00698-w.
2
Multiomics of Aging and Aging-Related Diseases.衰老及衰老相关疾病的多组学
Int J Mol Sci. 2024 Dec 21;25(24):13671. doi: 10.3390/ijms252413671.
3
Extracellular matrix in vascular homeostasis and disease.血管稳态与疾病中的细胞外基质
Nat Rev Cardiol. 2025 May;22(5):333-353. doi: 10.1038/s41569-024-01103-0. Epub 2025 Jan 2.
4
Proteomics, Human Environmental Exposure, and Cardiometabolic Risk.蛋白质组学、人体环境暴露与心血管代谢风险
Circ Res. 2024 Jun 21;135(1):138-154. doi: 10.1161/CIRCRESAHA.124.324559. Epub 2024 Apr 25.

本文引用的文献

2
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
9
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验